Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning.

Several other research firms also recently issued reports on ASND. JPMorgan Chase & Co. decreased their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. TD Cowen dropped their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Stifel Nicolaus boosted their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Bank of America raised their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Finally, Evercore ISI upped their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $191.77.

Ascendis Pharma A/S Stock Up 5.8 %

Shares of ASND opened at $129.81 on Wednesday. The company has a market capitalization of $7.87 billion, a price-to-earnings ratio of -16.07 and a beta of 0.66. Ascendis Pharma A/S has a 52-week low of $90.13 and a 52-week high of $161.00. The stock has a 50 day moving average price of $133.22 and a 200 day moving average price of $132.23.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, equities analysts anticipate that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors have recently bought and sold shares of the company. Westfield Capital Management Co. LP raised its stake in shares of Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after buying an additional 170,942 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after acquiring an additional 229,995 shares during the last quarter. Janus Henderson Group PLC raised its position in Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after acquiring an additional 267,881 shares during the last quarter. Capital International Investors lifted its holdings in shares of Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after purchasing an additional 10,044 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in shares of Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after purchasing an additional 155,971 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.